"The released double-stranded RNA is mistakenly identified by the cell as a sign of viral infection."
New Research Reveals How Defective Mitochondria Fuel Pancreatic Cancer Growth
A collaborative study by researchers at The Wistar Institute and ChristianaCare's Helen F. Graham Cancer Center & Research Institute has identified a critical mechanism linking defective mitochondria to tumor growth in pancreatic cancer. In preclinical models, blocking this pathway successfully halted cancer progression.
Key Findings
The research team discovered that pancreatic cancer cells frequently lack Mic60, a structural protein essential for mitochondrial integrity. This deficiency causes the mitochondrial membrane to break down.
- Defective mitochondria release double-stranded RNA into the cell.
- This RNA is detected by cellular sensors TLR3 and TRAF6.
- Detection triggers an inflammatory signaling cascade.
- Pancreatic cancer cells become dependent on this inflammation for growth and survival.
- Pharmacological inhibition of the TLR3/TRAF6 pathway resulted in cancer cell death in lab tests and stopped tumor growth in a mouse model.
- The intervention did not appear to harm normal cells.
Mechanistic Details
Normal mitochondria maintain their structure through the presence of Mic60. In tumor cells with low levels of this protein, the mitochondrial membranes become leaky. The released double-stranded RNA is mistakenly identified by the cell as a sign of viral infection, which activates the TLR3/TRAF6 signaling pathway and subsequent inflammation.
Statements from Researchers
"While it was known mitochondria could release double-stranded RNA and generate inflammation, this mechanism had not previously been identified in cancer or as a driver of cancer growth."
— Dario Altieri, M.D., President and CEO, The Wistar Institute
"This finding identifies a genuine vulnerability in the cancer itself that may be exploitable therapeutically."
— Nicholas Petrelli, M.D., Director, Cawley Center for Translational Cancer Research, ChristianaCare
Background
Pancreatic cancer is an aggressive malignancy characterized by limited treatment options and a poor prognosis. It is often diagnosed at a metastatic stage. Mitochondrial dysfunction is common in tumor cells, but this study marks the first time it has been linked to inflammation-driven cancer growth in this context.
Next Steps & Funding
Researchers plan to investigate how Mic60 deficiency damages mitochondrial membranes. They also intend to develop a TLR3/TRAF6 inhibitor as a potential therapy.
The study was supported by National Institutes of Health grants R35 CA220446, R50 CA221838, and R50 CA211199; the Cotswold Foundation; and National Cancer Institute grant P30 CA10815.
Publication
The study, titled "Mitochondrial Double-Stranded RNA Fuels Pancreatic Cancer Growth Via RIG-I/TLR3 Inflammation," was published in the Proceedings of the National Academy of Sciences in 2026.